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Effects of PCBs and Related Compounds
on Hepatocarcinogenesis in Rats and Mice
by Stuart Sleight*
Commercial mixtures of polychlorinated biphenyls (PCBs) and polybrominated biphenyls (PBBs) can
cause hepatocellular carcinoma in rats and mice. Present evidence indicates that these chemicals act as
promoters and not initiators ofhepatocarcinogenesis. Our results show that Firemaster BP-6 (FM) and its
nontoxicmajorcongener, 2,2',4,4',5,5'-hexabromobiphenyl (HBB), actas promoters in thetwo-stage model
for hepatocarcinogenesis devised by Pitot and associates. A toxic congener, 3,3',4,4',5,5'-HBB, also was
assessed for tumor-promoting activity. This congener, though not in FM, is similar to TCDD, in that both
cause 3-methylcholanthrene (MC)-type induction of hepatic microsomal enzymes and produce similar
toxic responses. FM contains several congeners which are mixed-type inducers in thatthey induce MC-type
and phenobarbital (PB)-type enzymes. The toxicity of FM is most likely associated with its congeners
which are mixed-type inducers and not to relatively nontoxic congeners such as 2,2',4,4',5,5'-HBB which
are strictly PB-type inducers. Congener 3,3',4,4',5,5'-HBB acted as a tumor promoter only at a dose that
was hepatotoxic. A synergistic effect on tumor promoting ability was produced by combining a nontoxic
and nonpromoting dose of 3,3',4,4',5,5'-HBB with a promoting dose of 2,2',4,4',5,5'-HBB. Our results
suggest that synergism between toxic and nontoxic congeners in FM mayexplain why mixtures such as FM
have greater promoting abilitythan individual congeners. Ourresults also indicatethatwithPBB, toxicity
and carcinogenicity are not necessarily related.
One of the major concerns of people exposed to
environmental chemicals such as polychlorinated biphe-
nyls (PCBs) is whether or not these chemicals are
carcinogenic. Although epidemiologic studies have not
conclusively shown a greater cancer risk for people as a
result of PCB exposure, there is conclusive evidence
that PCBs can cause hepatic cancer in rodents. Pro-
longed dietary administration of PCB mixtures has
induced hepatic tumors in rats (1-4) and mice (5-7).
Hepatocellular carcinomas were described in each spe-
cies and, in addition, what are classified as neoplastic
nodules and foci of cellular alteration were described
(8).
Evidence to date strongly indicates that the mixtures
of PCBs act as promoters of hepatic carcinogenesis.
When PCBs were given to rats after an initiator such as
diethylnitrosamine there was convincing evidence that
they had a tumor promoting effect in the liver (9,10).
Thmor promotion was also evident when impurities
such as dibenzofurans were removed from the PCB
mixture (10). Earlier, Kimura et al. (11) reported a high
incidence of hepatocellular carcinomas in the livers of
rats fed a diet containing a tumor initiator, 3'-methyl-
4-dimethylaminoazobenzene, for 2 months followed by
dietary administration of Kanechlor 400, a commercial
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mixture ofPCBs, for 6 months. Since administration of
the initiator by itself or administration of Kanechlor
before or concurrently with the initiator did not result
in hepatic tumors, the authors interpreted the results
as indicative of a tumor promoting effect by PCBs.
Recently, emphasis has shifted to counting and meas-
uring preneoplastic enzyme-altered foci in the liver as
an indicator ofthe tumorpromoting ability ofchemicals
such asPCBs. Thereis considerable evidence thatthese
foci are precursor lesions of hepatocellular carcinomas
(12-17) andtheymostlikelyrepresentthefirsthistologi-
cally verifiable step in the sequential development of
hepatic neoplasia. Bycomparingthenumberofenzyme-
altered foci resulting from administration of the initia-
tor alone with the number and area of foci resulting
from administration of the initiator and then the sus-
pected promoter, one can obtain an assessment of the
tumor promoting effects ofchemicals such as PCBs. By
using such procedures, Deml and Oesterle (18) found
that Clophen A 50, a commercial mixture ofPCBs, had
greater promoting effects in livers from female rats
when compared to the effects in males. They also
reported that weanling rats were much more suscepti-
ble to the promoting effects of PCBs than adult rats
(19).
When studying PCBs and related chemicals as to
their carcinogenic effects, the timing of administration
is important (20). These chemicals are potent inducersS. SLEIGHT
of hepatic microsomal enzymes and these enzymes can
metabolize manycarcinogens to less potentmetabolites.
Therefore, if PCBs are given to rodents before the
administration ofhepatocarcinogens such as 3'-methyl-
4-dimethylaminoazobenzene or diethylnitrosamine, an
inhibitory effect on hepatocarcinogenesis can occur (21).
Further studies are needed on the inhibitory or enhanc-
ing effects of PCBs on carcinogens.
The PBBs, as an environmental pollutant, came to
public attention as a result of accidental contamination
of animal feed in Michigan in 1973 (22). As a result of
this accident, most people in Michigan have PBBs in
their body tissues, and considerable public concern
exists as to long-term effects such as cancer. Since
PCBs and PBBs are closely related chemicals, it is not
surprising that biological responses to these chemicals
are nearly identical. Oral administration of PBBs has
caused hepatocellular carcinomas in rats (23,24) and
mice (24).
At Michigan State University we have studied the
pathologic effects ofPBBs in rats with special emphasis
on the effects of purified PBB congeners (25-27). We
have found that 2,2',4,4',5,5'-hexabromobiphenyl, the
major congener in Firemaster BP-6 (FM), the commer-
cial mixture of PBBs, is relatively nontoxic. This
congener is strictly a phenobarbital (PB)-type inducer
of hepatic drug metabolizing enzymes (28). Other con-
geners in FM such as 2,3,4,4',5-pentabromobiphenyl,
2,2',3,4,4',5-hexabromobiphenyl(HBB),2,3,4,4',5,5'-HBB
and 2,3,3',4,4',5-HBB, not only induce enzymes in-
duced by PB but also induce enzymes induced by
3-methylcholanthrene (MC). These congeners, like the
mixture, are classified as mixed-type inducers and most
likely account for most ofthe toxicity ofthe commercial
product (29,30).
We have used the Pitot protocol (31) to assess the
tumor-promoting activity of PBBs because it clearly
separates the initiation stage from the promotion stage.
Initiation consists of a 70% partial hepatectomy of200-g
female rats followed 24 hr later by a subcarcinogenic
dose (10 mg/kg body weight) of diethylnitrosamine
(DEN). The promotion phase ofthe protocol consists of
dietary administration of the test chemical starting 30
days after initiation. We use PB at a dietary concentra-
tion of500mg/kg as astandard tumorpromoter and as a
basis for comparison for our test chemicals. Tumor-
promoting ability is assessed by counting and measur-
ing enzyme-altered hepatic foci exhibiting y-glutamyl
transpeptidase activity. By using this protocol, we have
demonstrated that FM and 2,2',4,4', 5,5'-HBB can act
as tumor promoters in experimental hepatocarcino-
genesis in rats (32). These results were predicted by
Trosko and associates since the PBB mixture and
2,2',4,41,5,5'-HBB both inhibit in vitro cellular commu-
nication at noncytotoxic doses, a property of known
tumor promoters (33-35).
In our assays, we found that diets containing 10 or
100 mg/kg of either FM or 2,2',4,4',5,5'-HBB had
hepatic tumor-promoting ability. However, FM caused
significantly more enzyme-altered foci to develop than
did the purified congener. These results indicate that
other congeners in FM are very effective as promoters
orpossiblythe combination ofcongeners with mixed- or
PB-type of microsomal enzyme induction have a syner-
gistic or additive effect on promotion.
We have also assessed the capacity of 3,3',4,4',5,5'-
HBB to act as a tumor promoter (36). This congener,
though apparently not in FM, is ofimportance because
it is similar to 2,3,7,8-tetrachlorodibenzo-p-dioxin in
that both cause MC-type induction of hepatic micro-
somal enzymes and produce characteristic toxic and
histologic responses (27,37). In Trosko's in vitro assay,
this congener did not inhibit metabolic cooperation at
noncytotoxic doses and, therefore, was predicted not to
be a tumor promoter (35). Our studies in rats have
shown that nonhepatotoxic doses ofthis congener (0.01
and 0.1 mg/kgin the diet) are not tumorpromoters even
though these doses elicit MC-type enzyme induction. A
hepatotoxic dose of 3,3',4,4',5,5'-HBB caused severe
hepatocellular enlargement and vacuolation and focal
areas of necrosis. At this dose, tumor promoting
activity was seen; the mechanism ofwhich is mostlikely
associated with hepatic cell hyperplasia secondary to
chronic hepatotoxicity. We concluded that two mecha-
nisms oftumor promotion by PBBs can occur. With the
nontoxic congeners such as 2,2',4,4',5,5'-HBB, the
tumor promoting effect is a direct one, possibly associ-
ated with interference in normal cell-to-cell communica-
tion. Toxic congeners may exert their effects less
directly by causing chronic hepatotoxicity. Chronic or
recurrentnecrosis ofhepaticcells canresultinregenera-
tive stimuli and be a mechanism of tumor promotion
(38). Hepatic cells initiated by DEN may also be
resistant to the effects of cytotoxic chemicals such as
3,3',4,4',5,5'-HBB and have an increased responsive-
nesstoendogenous orexogenousgrowth stimuli(39,40).
It is our contention that it is important to distinguish
between tumor promoters that can exert effects at
noncytotoxic doses and those that can only promote as a
secondary effect of hepatic necrosis.
Kimbrough (41) hypothesized that since PCBs and
PBBs are lipophilic and highly persistent in the body
that it should not be necessary to feed these chemicals
for extended periods to assess toxic or carcinogenic
effects. She reported that a single dose of1 g/kgofbody
weight or smaller amounts over a short period of time
resulted in a high incidence of hepatocellular carcino-
mas in rats (23). We have also found that PBB given
without an initiator enhanced the development of a
small number of enzyme-altered foci. One interpreta-
tion ofthese results is that PBBs are complete carcino-
gens and, therefore, can act asinitiators and promoters.
Although these chemicals have not been shown to be
genotoxic or mutagenic (42-44), as would be expected if
they were initiators, the possibility ofinitiating activity
cannot be ruled out as yet. However, carcinogenic
activity of a promoter such as PBBs apparently can
occur as a result of promotion of "environmentally
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initiated" cells (45,46). We conclude that the lack of
evidence that PBBs are mutagenic or genotoxic, the
positive correlation ofinhibition ofintercellular commu-
nication in vitro and the ability to enhance development
ofenzyme-altered foci in an initiation/promotion system
supportourcontentionthatPBBsactstrictlyaspromot-
ers ofhepatocarcinogenesis. Recently we have obtained
further evidence that PBBs act as promoters by show-
ing that a summational effect is not seen when PBBs
are given prior to DEN. An enhancing effect on the
number of enzyme-altered foci occurs when PBBs are
given after DEN (47). Accordingto Williams et al. (48),
promoters do not have a summational or enhancing
effect when given prior to an initiator.
Kimbrough's observation that a single dose of PBBs
-and likely PCBs-results in hepatocellular carci-
noma in rats and recent work by us indicating that a
single dose of PBBs can effectively act as a tumor
promoter in an initiation/promotion assay have impor-
tant implications. Classic tumor promoters of hepato-
carcinogenesis such as phenobarbital are most effective
when given frequently over extended periods (49). For
persistent lipophilic compounds such as PBBs and
PCBs, continual exposure from external sources is not
needed for tumor promotion to occur.
We have produced a synergistic effect on tumor
promoting ability by PBBs by combining anontoxic and
nonpromoting dose of 3,3',4,4',5,5'-HBB (0.1 mg/kg of
diet) with a promoting dose of the nontoxic congener
2,2',4,4',5,5'-HBB (10 mg/kg in diet) (47,50). These
results help explain why FM, at certain concentrations,
has greater tumor promoting ability than individual
congeners in ourinitial studies (32). Aninhibitory effect
on tumor promotion was seen when atoxic and promot-
ing dose of3,3',4,4',5,5'-HBB (1 mg/kg) was combined
withapromotingdoseof2,2',4,4',5,5'-HBB (100mg/kg).
The results as to inhibitory effects may pertain to the
fact that there is not a dose related effect on tumor
promotion at higher concentrations ofchemicals such as
PBBs. For example, we see as many enzyme-altered
foci after a single dose of30 mg ofthe mixture ofPBBs
as we dowith adose of150 mgand see greaternumbers
of foci with either of these doses than when rats are
given 300 mg at a single dose in an initiation/promotion
assay (unpublished observations).
The similarity of chemical structure and similar
biological responses to exposure ofanimals to PBBs and
PCBs raises the possibility that additive or synergistic
effects on toxicity or tumor promotion may occur if
people or animals are exposed simultaneously to these
chemicals. People are especially concerned about this
possibility because their bodies may contain PCBs,
PBBs and other related chemicals such as dioxins.
Studies are now in progress in our laboratory in which
we are using a purified PCB congener, 3,3',4,4',5,5'-
HCB, and apurified PBB congener, 2,2',4,4',5,5'-HBB,
in combination studies to assess additive or synergistic
effects on toxicity or tumor promotion. We hypothesize
that our results will be similar to those seen in the
combination studies with PBB congeners. We did not
see an additive orsynergistic effect ontumorpromoting
ability when we combined 1 mg/kg ofFM with 1 mg/kg
of Aroclor 1254, a commercial mixture of PCBs.
However, dietary concentrations of 1 mg/kg of Aroclor
1254 significantly increased the number of enzyme-
altered foci after only 100 days of feeding in the
initiation/promotion assay we are using (unpublished
observations).
An obvious question when one uses the Pitot model
forinitiation/promotion and kills the rats before there is
evidence of hepatocellular carcinoma is whether or not
carcinomas would develop ifthe animals were allowed to
live for an extended time after the dietary treatment.
To test this possibility, we have given rats FM at 10
mg/kg in the diet for 140 days and then fed a basal diet
without FM for an additional 275 days. Although the
number of rats was small, all four rats in this experi-
ment had developed hepatocellular carcinomas whereas
none given only the basal diet after initiation had
tumors (47).
Our results are significant because they clearly show
that nontoxic components of FM such as 2,2',4,4',5,5'-
HBB can act as promoters of hepatocarcinogenesis in
the rat. Therefore, with PBBs, and most likely with
PCBs, toxicity and carcinogenicity are not necessarily
related. Our results also indicate that interactions
between chemically similar compounds with different
biological effects such as 2,2',4,4',5,5'-HBB and 3,3',
4,4',5,5'-HBB can have a potentiating or inhibitory
effect on hepatic tumor promoting ability. We also
believe it is important to distinguish between nontoxic
compounds that may have direct tumor promoting
activity and compounds which promote hepatic tumors
secondarily to chronic hepatotoxicity.
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